<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: To evaluate the efficacy and tolerability of once-weekly LY2189265 (LY), a novel glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi>-1 (GLP-1) IgG4-Fc fusion protein, in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> failing oral antihyperglycaemic medications (OAMs) </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Placebo-controlled, double-blind study in 262 patients (mean age 57 ± 12 years; BMI 33.9 ± 4.1 kg/m(2); and glycosylated <z:chebi fb="34" ids="35143">haemoglobin</z:chebi> A1c (A1c) 8.24 ± 0.93%) receiving two OAMs </plain></SENT>
<SENT sid="2" pm="."><plain>Patients were randomized to once-weekly subcutaneous injections of placebo or LY 0.5 mg for 4 weeks, then 1.0 mg for 12 weeks (LY 0.5/1.0); 1.0 mg for 16 weeks (LY 1.0/1.0); or 1.0 mg for 4 weeks, then 2.0 mg for 12 weeks (LY 1.0/2.0) </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: At week 16, A1c changes (least-squares mean ± standard error) were -0.24 ± 0.12, -1.38 ± 0.12, -1.32 ± 0.12 and -1.59 ± 0.12%, in the placebo, LY 0.5/1.0, LY 1.0/1.0 and LY 1.0/2.0 arms, respectively (<z:hpo ids='HP_0000001'>all</z:hpo> p &lt; 0.001 vs. placebo) </plain></SENT>
<SENT sid="4" pm="."><plain>Both fasting (p &lt; 0.001) and postprandial (p &lt; 0.05) blood <z:chebi fb="105" ids="17234">glucose</z:chebi> decreased significantly compared to placebo at <z:hpo ids='HP_0000001'>all</z:hpo> LY doses </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0001824'>Weight loss</z:hpo> was dose dependent and ranged from -1.34 ± 0.39 to -2.55 ± 0.40 kg at 16 weeks (<z:hpo ids='HP_0000001'>all</z:hpo> p &lt; 0.05 vs. placebo) </plain></SENT>
<SENT sid="6" pm="."><plain>At the highest LY dosage, the most common adverse events were <z:hpo ids='HP_0002018'>nausea</z:hpo> (13.8%), diarrhoea (13.8%) and <z:hpo ids='HP_0003270'>abdominal distension</z:hpo> (13.8%) </plain></SENT>
<SENT sid="7" pm="."><plain><z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">Hypoglycaemia</z:e> was uncommon overall (≤0.8 episodes/patient/30 days) but more common with LY than placebo through the initial 4 weeks (p &lt; 0.05) </plain></SENT>
<SENT sid="8" pm="."><plain>No differences in cardiovascular events or blood pressure were shown between treatments </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: LY2189265, given to overweight/<z:mp ids='MP_0001261'>obese</z:mp> patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> for 16 weeks in combination with OAMs, was relatively well tolerated and significantly reduced A1c, blood <z:chebi fb="105" ids="17234">glucose</z:chebi> and body weight </plain></SENT>
</text></document>